Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.53 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.53 |
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.53 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.53 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.53 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.53 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | HTT | P42858 | 4/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.53 |
| ▸ | RAD52 | P43351 | 3/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL5348732 | 1.00 | KMT2A (0.53) | KMT2ASMN1; SMN2HTTHSP90AA1RAD52 | |
| Bromide SCHEMBL28244601 | 1.00 | KMT2A (0.53) | KMT2ASMN1; SMN2HTTHSP90AA1RAD52 | |
| Bromide SCHEMBL22027189 | 1.00 | KMT2A (0.53) | KMT2ASMN1; SMN2HTTHSP90AA1RAD52 | |
| Bromide SCHEMBL17027659 | 1.00 | KMT2A (0.53) | KMT2ASMN1; SMN2HTTHSP90AA1RAD52 | |
| Bromide SCHEMBL3800991 | 1.00 | KMT2A (0.53) | KMT2ASMN1; SMN2HTTHSP90AA1RAD52 | |
| Bromide SCHEMBL22027172 | 1.00 | KMT2A (0.53) | KMT2ASMN1; SMN2HTTHSP90AA1RAD52 | |
| SCHEMBL5297852 | 0.98 | CHRM2 (0.52) | KMT2ASMN1; SMN2HTTHSP90AA1RAD52 | |
| SCHEMBL4058948 | 0.98 | CHRM2 (0.52) | KMT2ASMN1; SMN2HTTHSP90AA1RAD52 | |
| SCHEMBL5301397 | 0.98 | CHRM2 (0.52) | KMT2ASMN1; SMN2HTTHSP90AA1RAD52 | |
| Bromide SCHEMBL14896254 | 0.98 | KMT2A (0.50) | KMT2ASMN1; SMN2HTTHSP90AA1RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213907-A1 | SYSTEM FOR EXTINGUISHING FIRES | MOLEKULE GROUP, INC. (US) | 2025-07-03 | — | — | US | disclosed |
| US-12251589-B2 | System for extinguishing fires | MOLEKULE GROUP, INC. (US) | 2025-03-18 | — | — | US | disclosed |
| US-20220267772-A1 | IMMUNOSTIMULATORY SEQUENCE OLIGONUCLEOTIDES AND METHODS OF USING THE SAME | TRISALUS LIFE SCIENCES, INC. (US) | 2022-08-25 | — | — | US | disclosed |
| US-20220184442-A1 | SYSTEM FOR EXTINGUISHING FIRES | Molekule, Inc. | 2022-06-16 | — | — | US | disclosed |
| US-11312965-B2 | Immunostimulatory sequence oligonucleotides and methods of using the same | TRISALUS LIFE SCIENCES, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11291874-B2 | System for extinguishing fires | Molekule, Inc. (US) | 2022-04-05 | — | — | US | disclosed |
| EP-3894024-A1 | SYSTEM FOR EXTINGUISHING FIRES | Molekule, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| US-20200179737-A1 | SYSTEM FOR EXTINGUISHING FIRES | Molekule, Inc. | 2020-06-11 | — | — | US | disclosed |
| US-20190276829-A1 | IMMUNOSTIMULATORY SEQUENCE OLIGONUCLEOTIDES AND METHODS OF USING THE SAME | TRISALUS LIFE SCIENCES, INC. | 2019-09-12 | — | — | US | disclosed |
| US-10196643-B2 | Immunostimulatory sequence oligonucleotides and methods of using the same | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2019-02-05 | — | — | US | disclosed |
| US-20090068208-A1 | LONG TERM DISEASE MODIFICATION USING IMMUNOSTIMULATORY OLIGONUCLEOTIDES | DYNAVAX TECHNOLOGIES CORPORATION | 2009-03-12 | — | — | US | disclosed |
| US-20090017075-A1 | Immunomodulatory compositions, methods of making, and methods of use thereof | DYNAVAX TECHNOLOGIES CORPORATION | 2009-01-15 | — | — | US | disclosed |
| EP-1992635-A1 | Immunostimulatory sequence oligonucleotides and methods of using the same | Dynavax Technologies Corporation (US) | 2008-11-19 | — | — | EP | disclosed |
| WO-2008073661-A2 | LONG TERM DISEASE MODIFICATION USING IMMUNOSTIMULATORY OLIGONUCLEOTIDES | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2008-06-19 | — | — | WO | disclosed |
| EP-1575977-A4 | IMMUNOSTIMULATORY SEQUENCE OLIGONUCLEOTIDES AND METHODS OF USING THE SAME | DYNAVAX TECH CORP (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20060058254-A1 | Immunostimulatory sequence oligonucleotides and methods of using the same | DYNAVAX TECHNOLOGIES CORPORATION | 2006-03-16 | — | — | US | disclosed |
| EP-1575977-A2 | IMMUNOSTIMULATORY SEQUENCE OLIGONUCLEOTIDES AND METHODS OF USING THE SAME | Dynavax Technologies Corporation (US) | 2005-09-21 | — | — | EP | disclosed |
| EP-1551376-A2 | IMMUNOMODULATORY COMPOSITIONS, METHODS OF MAKING, AND METHODS OF USE THEREOF | Dynavax Technologies Corporation (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004058179-A2 | IMMUNOSTIMULATORY SEQUENCE OLIGONUCLEOTIDES AND METHODS OF USING THE SAME | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004014322-A2 | IMMUNOMODULATORY COMPOSITIONS, METHODS OF MAKING, AND METHODS OF USE THEREOF | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267772-A1 | IMMUNOSTIMULATORY SEQUENCE OLIGONUCLEOTIDES AND METHODS OF USING THE SAME | TLR3, TLR9, CD74 | CHRM2 3567/4885CHRM1 4280/4885ACHE 4566/4885 |
| US-11312965-B2 | Immunostimulatory sequence oligonucleotides and methods of using the same | TLR3, TLR9, CD74 | CHRM2 3567/4885CHRM1 4280/4885ACHE 4566/4885 |
| US-20190276829-A1 | IMMUNOSTIMULATORY SEQUENCE OLIGONUCLEOTIDES AND METHODS OF USING THE SAME | TLR3, TLR9, CD74 | CHRM2 3567/4885CHRM1 4280/4885ACHE 4566/4885 |
| US-10196643-B2 | Immunostimulatory sequence oligonucleotides and methods of using the same | TLR3, TLR9, CD74 | CHRM2 3567/4885CHRM1 4280/4885ACHE 4566/4885 |
| US-20060058254-A1 | Immunostimulatory sequence oligonucleotides and methods of using the same | TLR3, TLR9, CD74 | CHRM2 3567/4885CHRM1 4280/4885ACHE 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.